| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4026128 | Ophthalmology | 2014 | 9 Pages |
Abstract
A regimen combining melphalan and topotecan for SSOAI treatment of retinoblastoma is active and well tolerated. This combination chemotherapy previously showed synergistic pharmacologic activity, and we herein provide evidence of not increasing the hematologic toxicity compared with single-agent melphalan.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Paula BSc, Alejandro MD, Emiliano BSc, Claudia MD, Adriana MD, Francisco MD, Evandro MD, Livia MD, Guillermo L. MD, PhD, Paula PhD,